KNOWLEDGE BANK

Interviews

Engineering the Future of Pneumococcal Conjugate Vaccines (PCV)

PhD, Chemical and Biotechnology, Savitribai Phule Pune University. Manager-Manufacturing, Inventprise Inc
Walmik Karbhari Gaikwad PhD is a seasoned biopharmaceutical expert with years in vaccine RD and manufacturing His PhD research pioneered costeffective processes for pneumococcal conjugate vaccines holds scholarly publications international patents and serves on editorial boards Based in Seattle currently works on cGMPcompliant process development and production at Inventprise Inc

Articles

Use of Steroids in COVID-19 patients

COVID is already declared as pandemic by World Health Organization and various new strains are also emergning across the globe and creating havoc Vaccines are developed and showing a promising results in the prevention of this infection The role of vaccine against new strains is complelty unclear so far Further till now no specific drug

Research Insights

Validation Of A Liquid Chromatographic Method For The Pharmaceutical Quality Control Of Products Containing Elacridar

Abstract Many anticancer drugs have an impaired bioavailability and poor brain penetration because they are substrates to drug efflux pumps such as Pglycoprotein and Breast Cancer Resistance Protein Elacridar is a strong inhibitor of these two drug efflux pumps and therefore has great potential to improve oral absorption and brain penetration of many anticanc

Case Studies

Open Innovation in Pharmaceutical Industry: A Case Study by Eli Lilly

Abstract Interest on Open Innovation paradigm has seen a phenomenal increase since last two decades especially when Henry Chesbrough coined this term in triggering the creation of a new whole body of knowledge However all of his research work could not come up with a standardized allinone theory Instead we find a heterogeneous series of models tha

Techno Trends

New Approach to Manipulating GPCRs

Gproteincoupled receptors or GPCRs are the most important signalling mechanism in human cells They react on exposure to the nutrients toxins hormones and light particles The major blockbuster drugs target the GPCRs for treatment of many diseases including heart disease cancer diabetes depression and arthritis These drugs affect GPCRs behaviour external to the cells Re...

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

TOP ARTICLES

1

Demystifying Lead-time bias and Length-time bias in Clinical Trials

Jefry Winner G

Jefry Winner G has completed his MBBS from Vinayaka Missions Medical College. He is currently pursuing a Doctorate of Medicine in Pharmacology at JIPMER Puducherry. He is interested in clinical research and is currently involved in an academic clinical trial involving Epilepsy. He has four years of clinical experience in healthcare and Academia. His area of interest includes Clinical trials, Pharmacotherapeutics, Drug safety, and clinical pharmacology. He also has over 15 publications in peer-reviewed journals.

 

2

Nanotechnology based Drug Delivery for Infectious Diseases

Dr. Vinod Kumar Rajana

Dr. Vinod Kumar Rajana, Assistant Professor of Pharmaceutics, specializes in nanotechnology, bioassays, and infectious disease research. With expertise in nanoparticle synthesis, biotechnology, and drug delivery, his work integrates green chemistry with pharmaceutical innovation to develop sustainable, low-cost nanomaterials for topical antifungal and anticancer therapies, water purification, and biomedical applications.

3

The Green Revolution in Medicine

Aishwarya Jain

Dr Aishwarya Jain is an Assistant Professor and award-winning pharmaceutical researcher recognised with over 70+ national and international honours. Her research focuses on green synthesis, nanotechnology, and sustainable drug delivery. A SCOPUS journal editor and published author, she is dedicated to advancing eco-friendly pharmaceutical innovation and inspiring the next generation of researchers.

4

Harnessing Artificial Intelligence

Anita-Ioana Visan

Anita-Ioana Visan, a Scientific Researcher 2nd degree, at the Laser-Surface-Plasma Interactions (LSPI) Laboratory, Lasers Department, National Institute for Lasers, Plasma and Radiation Physics (INFLPR) in Magurele, is an expert in nanopowders synthesis and characterisation, as well as thin coatings of calcium phosphates, biopolymers, flavonoids, antibiotics, and antimicrobial peptides synthesized by Pulsed Laser Deposition, Matrix Assisted Pulsed Laser Evaporation, and Combinatorial-MAPLE. Moreover, she has a profound knowledge of thin films characterisation methods, including UV-Vis, FTIR, XRD, SEM, AFM, fluorescence microscopy, electrochemical, magnetic induction, biodegradation, and antimicrobial tests. With her current research focusing on the cutting-edge fields of artificial neural networks, drug repurposing, and pharmaceutical AI, she is paving the way for innovative solutions that have the potential to revolutionise the field of medicine. If you would like to contact her, please use the following email address: anita.visan@inflpr.ro. Furthermore, you can find her professional profile at https://orcid.org/0000-0003-0539-4160.

 

Irina Negut

Irina Negut is a Scientific Researcher 2nd degree, at the National Institute for Lasers, Plasma and Radiation Physics (INFLPR) in Magurele, Romania. She has important experience in fabricating and investigating the characteristics and (bio) functionality of nano-sized/-structured materials (including composite and hybrid particles, thin films and laser-processed coatings). Her research activity includes coating synthesis by laser-assisted techniques. She is also highly experienced in evaluating the compositional and microstructural aspects of nanomaterials and coatings, but also in assessing their optical, thermal, electrical, and electrochemical properties. If you would like to contact her, please use the following email address: negut.irina@inflpr.ro. Her professional profile can be found at https://orcid.org/0000-0003-4038-7548.

 

5

Peptide-Drug Conjugates in Precision Oncology

Dr. Keykavous Parang

Dr. Keykavous Parang is a professor at Chapman University with expertise in peptide-based therapeutics and targeted drug delivery systems. He has published extensively in bioconjugate chemistry and nanomedicine, focusing on translating innovative molecular platforms into clinically viable cancer treatments.

Thuy Do

Thuy Do is a Pharm.D. student at Chapman University School of Pharmacy with research interests in nanomedicine and cancer therapeutics. She is involved in Dr. Parang’s capstone project, focusing on peptide-based conjugates and nanoparticle drug delivery systems for the development of innovative targeted cancer treatments.

Clare Dinh

Clare Dinh ('27) is a second-year PharmD student at Chapman University with a leadership emphasis. Active in various professional organizations, she is passionate about pharmaceutical research and plans to pursue postgraduate residency or fellowship programs to further her professional career.

Mahsa Moazen

Mahsa Moazen is a PharmD student at Chapman University and a researcher in Dr. Parang’s peptide drug conjugates project. She earned her bachelor’s degree in Pharmaceutical Chemistry. Her academic interests focus on peptide conjugates for targeted cancer therapy, bridging pharmaceutical research and clinical practice to advance innovative drug development.”

Troy Khong

Troy Khong is a PharmD student at Chapman University School of Pharmacy, set to graduate with a Pharm.D. with a Leadership Degree Emphasis in 2027. I am excited to continue growing in the field of pharmacy and look forward to pursuing opportunities related to pharmaceutical industry.

press releasesRead more...

Sino Biological Introduces AI-Trusted and Qualified Target Protein Collections for AI-Driven Discovery

As AI accelerates recombinant protein and antibody discovery for therapeutic and diagnostic development access to wellcharacterized target proteins is essential for evaluating AIdesigned molecules Sino Biological Inc Shenzhen Stock Exchange SZ a global biotechnology company

Collaboration aims to accelerate development of next generation medicines

The Personalised Medicine Centre PMC a joint initiative between Murdoch University and the Perron Institute biotechnology company Syngenis Labs and the Perron Institute are collaborating to establish a specialised preclinical safety testing platform for RNAbased medicines designed to treat diseases...

ITM and AtomVie Global Radiopharma Enter Supply Agreement for n.c.a. Lutetium-177

ITM Isotope Technologies Munich SE ITM a leading radiopharmaceutical biotech company and AtomVie Global Radiopharma AtomVie a radiopharmaceutical contract development and manufacturing organization CDMO today announced a supply agreement

Evotec and Bristol Myers Squibb advance strategic protein degradation partnership with second IND acceptance

Evotec SE NASDAQ EVO Frankfurt Prime Standard EVT today announced that its strategic protein degradation partnership with Bristol Myers Squibb has received a second Investigational New Drug IND acceptance from the US Food

Introducing Cognizant® Patient Hub Operations: AI-enabled patient access offering designed to shorten the path from prescription to therapy

Cognizant Nasdaq CTSH today introduced Cognizant Patient Hub Operations an offering built on NVIDIA accelerated computing that pairs AI agents with healthcareexperienced specialists to support patients and help drive better access to therapy

Thermo Fisher Scientific Launches Gibco™ VaxEvo™ CD 293 Medium to Advance Adenovirus Vaccine Production

Thermo Fisher Scientific the world leader in serving science today announced the Gibco VaxEvo CD Medium a chemically defined and animal originfree medium designed to support suspension HEK cell growth and hightiter adenovirus production

EventsRead more...

24 - 27

Nov 2026

Pharmtech & Ingredients 2026

Crocus Expo, Pavilion 2, Mosco...

24 - 25

Nov 2026

BioPharma Deals Conference 2026

Science Congress Center, Munic...

26 - 28

Nov 2026

One Health Conference 2026

Thapar Institute of Engineerin...

01 - 03

Dec 2026

Pharmaceutical Launch Excellence Summit

Novotel Amsterdam City, Nether...

01 - 03

Dec 2026

10th Antifibrotic Drug Development

Boston, MA at the Hotel Common...

02 - 04

Dec 2026

Genome Informatics 2026

Wellcome Genome Campus, UK

03 - 04

Dec 2026

03 - 04

Dec 2026

LATEST NEWSRead more...

Bionsight Enters into Collaboration with Astellas to Develop Autoimmune Disorder Therapy

Bionsight has entered into a global research and development RD collaboration with Astellas Pharma to explore a potential firstinclass treatment for autoimmune disorders

Isomorphic Labs Enters into Collaboration with MSD for Cancer Drug Discovery

Isomorphic Labs has entered into a strategic research collaboration with MSD to discover smallmolecule drug candidates for an important oncology target

Sanofi Receives Approval for Infilbray to Treat Neurological Symptoms of Type 3 Gaucher Disease

Sanofi has received approval from the US Food and Drug Administration FDA for Infilbray venglustat an oral medicine for treating neurological manifestations of Type Gaucher disease GD in adults and children weighing at least kg

Pfizer Enters into Agreement with Starna Therapeutics for Autoimmune Disease Treatments

Pfizer has entered into an exclusive licensing agreement with biotechnology company Starna Therapeutics to develop RNAbased in vivo chimeric antigen receptor Tcell CART therapies for autoimmune diseases

OXB Partners with Aura Biosciences for Drug Manufacturing

OXB has confirmed a manufacturing and supply partnership with Aura Biosciences

GSK Receives Approval for Nelkarmi to Treat Advanced ALK-Positive Lung Cancer

GSK plc LSENYSE GSK has received accelerated approval from the US Food and Drug Administration FDA for Nelkarmi neladalkib a treatment for adults with locally advanced or metastatic anaplastic lymphoma kinase ALKpositive nonsmall cell lung cancer NSCLC